Does Z17.1 require prior authorization?

No, Z17.1 does not require prior authorization (high confidence). Code is covered without prior authorization.

`Z17.1` — Estrogen receptor negative status [ER-]

ICD-10-CM

No Prior Auth Required

Code is covered without prior authorization (high confidence)

For NGS performed on or after 2022-01-01, bill using CPT code 81523 adjacent to the appropriate DEX Z‑Code identifier in the claim narrative.
Enter '1' in the Days/Unit field on the claim for MammaPrint services.
For CPT non‑NOC codes, submit the required information using SV101-7 or SV202-7 (preferred) or the NTE field.
For Part B electronic claims, place the DEX Z‑Code adjacent to the CPT code in Loop 2400 or SV101-7 for 837P; for Part B paper claims place the DEX Z‑Code in Box 19.

MammaPrint is indicated to analyze the gene expression profile of FFPE breast cancer tissue to assess a patient's risk for distant metastasis.
MammaPrint is validated for use in early‑stage breast cancer (MINDACT) and may be used for patients with early‑stage breast cancer to inform risk of distant metastasis.
MammaPrint is used to analyze gene expression of FFPE breast cancer tumor tissue to assess a patient's risk of distant metastasis.
The test may be performed using either the FDA-cleared microarray assay or an NGS-based assay shown to be technically equivalent.
MammaPrint is covered when performed on formalin-fixed, paraffin-embedded (FFPE) breast cancer tissue to assess a patient's risk for distant metastasis in early-stage breast cancer.
MammaPrint testing of formalin-fixed paraffin-embedded (FFPE) breast cancer tissue is used to assess a patient's risk for distant metastasis, and is indicated in early-stage breast cancer as validated in the MINDACT trial.

A55175 — Billing and Coding: MolDX: MammaPrint

J05

L36807 — MolDX: Molecular Diagnostic Tests (MDT)

J05

L36715 — BRCA1 and BRCA2 Genetic Testing

J12

A56542 — Billing and Coding: BRCA1 and BRCA2 Genetic Testing

J12

A54194 — Billing and Coding: MolDX: MammaPrint

Ask Verity about documentation requirements, denial risks, or coverage in your state.